Alzheimer's Disease Flashcards Preview

Y2 LCRS 1 - Pharmacology and Therapeutics - Laz COPY > Alzheimer's Disease > Flashcards

Flashcards in Alzheimer's Disease Deck (13)
Loading flashcards...
1
Q

What is the main risk factor for Alzheimer’s?

A
  • Age
2
Q

Describe the genetic component to Alzheimer’s - 3 genes

A
  1. APP – mutations in the amyloid precursor protein → early onset of Alzheimer’s disease
  2. PSEN – mutations in presenilin gene → increase likelihood of early onset Alzheimer’s disease
  3. ApoE (8%) – Apo Lipoprotein E mutation → increased likelihood of late onset Alzheimer’s
3
Q

List the clinical symptoms of Alzheimer’s disease

A
  • Memory loss – especially recently acquired information – MOST PROMINENT SYMPTOMS
  • Disorientation/confusion – forgetting where they are
  • Language problems – stopping in the middle of a conversation
  • Personality changes – becoming confused, fearful, anxious
  • Poor judgement – such as when dealing with money
4
Q

Outline the beta-amyloid hypothesis for Alzheimer’s disease

A
5
Q

Outline the tau hypothesis for Alzheimer’s disease

A
6
Q

Outline the inflammation hypothesis for Alzheimer’s disease

A
7
Q

What are the functions of microglia in the brain?

A
  1. Phagocytic role
  2. Secrete inflammatory mediators
  3. Neuro-protective role
8
Q

What are the 2 types of drugs used to treat Alzheimer’s?

A
  1. Anticholinesterase
  2. NMDA receptor blocker
9
Q

Give the 3 anticholinesterase drugs used for treating Alzheimer’s and expand on their mode of action

A
  1. Donepezil
    * Reversible cholinesterase inhibitor
  2. Rivastigmine
    * Pseudo-reversible AChE and BChE inhibitor
  3. Galantamine
  • Reversible cholinesterase inhibitor
  • Also direct alpha-7 nAChR agonist
10
Q

Why is there an adverse side effect profile with Rivastigmine?

A
  • Rivastigmine is a pseudo-reversible AChE and BChE inhibitor
  • BChE is both present in neural tissue but also in liver tissue, it is a liver enzyme so it causes far ranging side effects
11
Q

Give the name of one NMDA receptor blocker used to treat Alzheimer’s and give its mode of action, also in particular who is it prescribed for?

A
  • Memantine
  • Use-dependent non-competitive NMDA receptor blocker with low channel affinity
  • I.e. the more the NMDAr is activated, the more likely memantine is to have an inhibitory effect
  • Only prescribed for people with moderate to late stage alzheimer’s
12
Q

Give 3 examples of Alzheimer’s treatment failures in terms of the type of drug / mode of action, and give some named examples where possible

A
  1. Gamma-secretase inhibitors
  • Tarenflurbil
  • Semagacestat
  1. Beta-amyloid monoclonal antibodies (target beta-amyloid plaques)
  • Bapineuzumab
  • Solanezumab
  1. Tau inhibitors
    * Methylene blue
13
Q

1) Give more detail on the mode of action of Tarenflurbil & Semagacestat
2) Why is Semagacestat actually dangerous?

A

1)

  • Tarenflurbil - gamma secretase inhibitor that binds to the amyloid precursor protein (APP) molecule
  • Semagacestat - small molecule g-secretase inhibitor

2)

  • Causes skin cancer – inhibits the NOTCH pathway